Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company developing genetic medicines and other therapies for neurological diseases, including Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease and Huntington’s disease. Its TRACER platform discovers adeno-associated virus capsids designed to… From the company’s description.
Over the twelve months to Sep 30, 2026, Voyager Therapeutics, Inc. reported revenue of $25.11M, down 19.8% from a year earlier, and a net loss of $104.53M. Its operating margin was −450.1%, and operations used $109.19M in cash. In fiscal 2025, it reported revenue of $40.37M, down 49.5% from fiscal 2024, and a net loss of $119.72M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Voyager Therapeutics, Inc. does
In the company’s own words
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company developing genetic medicines and other therapies for neurological diseases, including Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease and Huntington’s disease. Its TRACER platform discovers adeno-associated virus capsids designed to cross the blood-brain barrier after intravenous dosing, while its Voyager NeuroShuttle platform uses receptor-binding molecules to deliver non-viral therapeutics to the brain. The company’s wholly owned pipeline includes VY1706, a tau-silencing gene therapy, and VY7523, an anti-tau antibody, both for Alzheimer’s disease, as well as an early-stage NeuroShuttle research program. Partnered programs include gene therapies for Friedreich’s ataxia and GBA1-related disease with Neurocrine, and programs for spinal muscular atrophy, Huntington’s disease and other targets with Novartis; it has also licensed capsids to Alexion. Voyager works with pharmaceutical and biotechnology partners through research collaborations, licenses and options, and retains options to participate in development and commercialization of selected programs. Substantially all revenue to date comes from collaborations and licensing agreements. Its website is www.voyagertherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- LEXINGTON, MA
- Fiscal year end
- December
- CIK
- 1640266
- SIC
- 2836
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Voyager Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Voyager Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Voyager Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Voyager Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Voyager Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”